The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie (ABBV) announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a ...

Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

BofA reinstated coverage of AbbVie (ABBV) with a Neutral rating and $191 price target AbbVie is a relatively “quiet” stock with durable ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/91.IM06wodO.js ...

Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...

The stock's fall snapped a two-day winning streak.

AbbVie, which in September reported that tavapadon had met the primary and secondary endpoints in a Phase 3 fixed-dose monotherapy trial, said it is on track to file for Food & Drug Administration ...